Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

All traffic has been stopped on the M5 after a crash near Bristol this evening (Monday, December 30). The collision took ...

BRISTOL, Va. (WDBJ) - Fire crews were called back to the former Virginia Intermont College campus in Bristol this past ...

We recently compiled a list of the Long-Term Stock Portfolio: Best Stocks for 10 Years. In this article, we are going to take ...

This was the stock's second consecutive day of losses.

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

Bristol has been named in the top ten venues for a stag do in Europe - and is now above Amsterdam and Krakow. And according ...

BRISTOL, TENN. (WCYB) — The signs are up for a new restaurant in Bristol, Tennessee. Work is underway for a Cook Out ...

IL2-CD25 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Autoimmune Disorders.

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Follicular Lymphoma.

There are few cities in the UK that bounce to the beat of the night like Bristol, and you can bet that when it comes to New Year's Eve, they aren't planning on doing it any differently.